SGLT2 inhibitors and GLP-1 RAs decreased UACR by 19-22% and 17-33%, respectively, compared to placebo in patients with type 2 diabetes over a median follow-up of ≥ 2 years.
Systematic Review
Do novel antidiabetic drugs (SGLT2 inhibitors, GLP-1 RAs, DPP-4 inhibitors) improve UACR and albuminuria outcomes compared to placebo in patients with type 2 diabetes?
SGLT2 inhibitors consistently improve UACR and albuminuria outcomes in patients with type 2 diabetes, providing long-term renoprotective benefits.
p-value: p=<0.05
INTRODUCTION: Albuminuria, or elevated urinary albumin-to-creatine ratio (UACR), is a biomarker for chronic kidney disease that is routinely monitored in patients with type 2 diabetes (T2D). Head-to-head comparisons of novel antidiabetic drugs on albuminuria outcomes remain limited. This systematic review qualitatively compared the efficacy of novel antidiabetic drugs on improving albuminuria outcomes in patients with T2D. METHODS: We searched the MEDLINE database until December 2022 for Phase 3 or 4 randomized, placebo-controlled trials that evaluated the effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors on changes in UACR and albuminuria categories in patients with T2D. RESULTS: Among 211 records identified, 27 were included, which reported on 16 trials. SGLT2 inhibitors and GLP-1 RAs decreased UACR by 19-22% and 17-33%, respectively, versus placebo (P < 0.05 for all studies) over median follow-up of ≥ 2 years; DPP-4 inhibitors showed varying effects on UACR. Compared with placebo, SGLT2 inhibitors decreased the risk for albuminuria onset by 16-20% and for albuminuria progression by 27-48% (P < 0.05 for all studies) and promoted albuminuria regression (P < 0.05 for all studies) over median follow-up of ≥ 2 years. Evidence on changes in albuminuria categories with GLP-1 RA or DPP-4 inhibitor treatment were limited with varying outcome definitions across studies and potential drug-specific effects within each class. The effect of novel antidiabetic drugs on UACR or albuminuria outcomes at ≤ 1 year remains poorly studied. CONCLUSION: Among the novel antidiabetic drugs, SGLT2 inhibitors consistently improved UACR and albuminuria outcomes in patients with T2D, with continuous treatment showing long-term benefit.
Liu et al. (Mon,) conducted a systematic review in Type 2 Diabetes. SGLT2 inhibitors, GLP-1 RAs, and DPP-4 inhibitors vs. Placebo was evaluated on Change in UACR (p=<0.05). SGLT2 inhibitors and GLP-1 RAs decreased UACR by 19-22% and 17-33%, respectively, compared to placebo in patients with type 2 diabetes over a median follow-up of ≥ 2 years.